Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors

Inclusion Criteria: 1. Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1; 2. Availability of complete clinical and imaging data; 3. Life expectancy ≥ 12 weeks; 4. Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹/L or neutrophils ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN; 5. Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria; 6. Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks; 7. Ability to provide adequate tumor tissue for testing and research. Exclusion Criteria: 1. Women who are planning pregnancy, pregnant, or breastfeeding; 2. History of other malignant tumors or prior receipt of other anti-tumor therapies; 3. Poor or missing PET scan image quality of the probe that fails to meet analysis standards; 4. Presence of claustrophobia or other mental illnesses; 5. Any other conditions deemed by the investigators as inappropriate for participation in this study.